Privium Fund Management B.V. Crispr Therapeutics Ag Transaction History
Privium Fund Management B.V.
- $469 Million
- Q2 2025
A detailed history of Privium Fund Management B.V. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Privium Fund Management B.V. holds 44,700 shares of CRSP stock, worth $3.03 Million. This represents 0.46% of its overall portfolio holdings.
Number of Shares
44,700
Previous 60,097
25.62%
Holding current value
$3.03 Million
Previous $2.05 Million
6.31%
% of portfolio
0.46%
Previous 0.54%
Shares
10 transactions
Others Institutions Holding CRSP
# of Institutions
532Shares Held
68.7MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$690 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$379 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$249 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$222 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$193 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.28B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....